(Q34343213)

1 August 2017

0 references

Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression (English)

1 reference

1 August 2017

0 references

1 reference

1 reference

Andre C Kalil

1

1 reference

1 August 2017

Steven P LaRosa

series ordinal

2

1 reference

1 August 2017

publication date

17 July 2012

1 reference

Lancet Infectious Diseases

1 August 2017

published in

1 reference

1 August 2017

volume

12

1 reference

1 August 2017

issue

9

1 reference

1 August 2017

page(s)

678-686

1 reference

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

The epidemiology of sepsis in the United States from 1979 through 2000

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

The protein C pathway and sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Overexpressing endothelial cell protein C receptor alters the hemostatic balance and protects mice from endotoxin.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Efficacy and safety of recombinant human activated protein C for severe sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Risks and benefits of activated protein C treatment for severe sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Human recombinant activated protein C for severe sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Why are clinicians not embracing the results from pivotal clinical trials in severe sepsis? A bayesian analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Drotrecogin alfa (activated) in adults with septic shock.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Cost-effectiveness of activated protein C in real-life clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Drotrecogin alfa (activated): real-life use and outcomes for the UK

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units--an observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Activated protein C and hospital mortality in septic shock: a propensity-matched analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Activated protein C in septic shock: a propensity-matched analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Drotrecogin alfa (activated) in sepsis: initial experience with patient selection, cost, and clinical outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Evaluation of drotrecogin alpha use in a Belgian university hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

A large, single-centre UK registry of drotrecogin alfa-activated use.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

90-day follow-up of patients treated with Drotrecogin Alfa (activated) for severe sepsis: a Belgian open label study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

A prospective, observational study of Xigris Use in the United States (XEUS).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Activated protein C treatment: experience about 23 patients in the operative period

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Does recombinant activated protein C work in patients with severe sepsis?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Evaluating the use of recombinant human activated protein C in adult severe sepsis: results of the Surviving Sepsis Campaign

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970157-3

7 January 2021

10.1016/S1473-3099(12)70157-3

Identifiers

DOI

1 reference

1 August 2017

1 reference